



Cite this: DOI: 10.1039/c5cc09822j

Received 27th November 2015,
Accepted 23rd December 2015

DOI: 10.1039/c5cc09822j

www.rsc.org/chemcomm

Divergent reactivity of an indole glucosinolate yields Lossen or Neber rearrangement products: the phytoalexin rapalexin A or a unique β -D-glucopyranose fused heterocycle†

M. S. C. Pedras,* Q. H. To and G. Schatte‡


Transformation of 1-*t*-Boc-4-methoxyindole-3-glucosinolate under acidic conditions yielded the potent phytoalexin rapalexin A, providing its first biomimetic synthesis via Lossen type rearrangement, while a novel 1-thioimidocarbonyl- β -D-glucopyranose heterocyclic system was obtained under basic conditions via Neber type rearrangement.

Glucosinolates are plant metabolites that are precursors of isothiocyanates ($-N=C=S$, ITC) and other natural products produced in crucifer species.¹ Natural products containing the ITC group are both ubiquitous and structurally diverse. Notably, while the vast majority of ITCs produced in terrestrial plants are formed in complex pathways, generating glucosinolates from amino acids and culminating with Lossen type rearrangements,¹ marine animals use inorganic ITCs to add to an organic skeleton (Scheme 1).² ITCs have important defensive roles and are necessary for the survival of plants and animals in highly competitive environments.^{1,2} Along with these ecological functions, toxicological and epidemiological work suggests that plant ITCs have chemopreventive roles against certain types of cancer in mammals.^{3,4}

Rapalexin A (**4**) is a potent indole-ITC phytoalexin isolated from crucifers cultivated worldwide for oils (*e.g.* canola and rapeseed)

and other nutritional products (*e.g.* broccoli, cabbage, cauliflower, turnip).⁵ Phytoalexins are natural products produced *de novo* by plants in response to stress caused by biotic or abiotic factors. Under many circumstances, these natural defenses are crucial in plant resistance to diseases caused by microbial pathogens.⁶ For this reason, their occurrence and pathways continue to generate enormous interest and to stimulate work to discover ecologically sensible approaches that produce crops able to withstand microbial threats in pesticide free environments.^{6,7}

By analogy to other ITCs produced in crucifer species (Scheme 1), the biosynthetic pathway of rapalexin A (**4**) was proposed to start with the amino acid 4-methoxyindolyglycine (**1**), followed by formation of the glucosinolate glucorapassicin A (**2**), subsequent hydrolysis of the glucosyl residue and a spontaneous Lossen type rearrangement (Scheme 2). Recent biosynthetic studies with isotopically labeled precursors verified this proposal, although glucorapassicin A (**2**) was not included because its chemical synthesis was unsuccessful.⁸ Herein we report further work toward the synthesis of glucorapassicin A (**2**) leading to the first biomimetic route to rapalexin A (**4**) via Lossen rearrangement, and to a unique bicyclic glucose fused product (**14**) formed via Neber rearrangement. Details of the chemistry of these intriguing transformations are disclosed.




Scheme 1 Biosynthetic pathways of ITCs in terrestrial plants (N = ● is derived from the amino acid) and in marine animals.


Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, SK S7N 5C9, Canada. E-mail: s.pedras@usask.ca

† Electronic supplementary information (ESI) available: Syntheses, characterization and NMR spectra of new compounds. CCDC 1439164. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5cc09822j


‡ Current address: Department of Chemistry, Queen's University, 90 Bader Lane, Kingston, ON K7L 3N6, Canada.



Scheme 2 Biosynthetic pathway of rapalexin A (**4**) in crucifers.



Scheme 3 Classical chemical reactions known as Lossen and Neber rearrangements.




Scheme 4 General synthetic approaches to glucosinolates: AD, anomeric disconnection and HD, hydroxamate disconnection;¹² PG = protecting group.

The classical Lossen rearrangement involves the transformation of *O*-activated hydroxamic acids,⁹ whereas the Neber rearrangement occurs with *O*-activated ketoximes.^{10,11} Typically, *O*-activated substrates carry Ar/R-sulfonyl or Ar/R-acyl groups (Scheme 3); variations of these reactions discovered over several decades afford Lossen type and Neber type rearrangement products.^{9,10}

The syntheses of aryl and indolyl glucosinolates have been achieved using two approaches, the so-called “anomeric disconnection” (AD) and the “hydroxamate disconnection” (HD) (Scheme 4).¹² Using the hydroxamate disconnection,¹² previous attempts to synthesize glucorapassicin A (2) afforded 1-*t*-Boc-glucorapassicin A (10),⁸ which decomposed upon standing in either aqueous or organic solvents over a period of 24 h. For this reason, in this work another protecting group (MeSO₂) was used in further attempts to synthesize glucorapassicin A (2). Protection of 4-methoxyindole-3-carboxaldehyde (5) followed by oximation and chlorination using *N*-chlorosuccinimide¹³ afforded the expected hydroximoyl chloride¹² (chloro oxime or *N*-hydroxyimidoyl chloride), which upon coupling with β-D-thioglucopyranose tetraacetate afforded thiohydroximate 7 in excellent yield (Scheme 5).¹⁴ Sulfonation of 7 using the Py-SO₃ complex¹⁵ yielded sulfonic acid 8, which was transformed to 1-MeSO₂-glucorapassicin A (9) under basic conditions, in an overall yield of 48% (C₁₇H₂₁N₂O₁₂S₃K, calc. 541.0262, obtained 541.0258). 1-*t*-Boc-glucorapassicin A (10) (C₂₁H₂₇N₂O₁₂S₂K, calc. 563.1005, obtained 563.1011) was synthesized similarly (ESI⁺).


Attempts to deprotect 1-MeSO₂-glucorapassicin A (9) and 1-*t*-Boc-glucorapassicin A (10) under acidic conditions afforded



Scheme 5 Synthesis of 1-MeSO₂-glucorapassicin A (9).

four products: 1-MeSO₂-rapalexin A (11) and 1-MeSO₂-4-methoxyindole carbonitrile (12) from 1-MeSO₂-glucorapassicin A (9), and rapalexin A (4) and 4-methoxyindole carbonitrile (13) from 1-*t*-Boc-glucorapassicin A (10) (spectroscopic data in the ESI⁺). By contrast, deprotection of 1-MeSO₂-glucorapassicin A (9) or 1-*t*-Boc-glucorapassicin A (10) under basic conditions afforded consistently the major product X (14) (Scheme 6). That is, to our disappointment, the desired product glucorapassicin A (2) (C₁₆H₁₉N₂O₁₀S₂) was not obtained. Remarkably, formation of rapalexin A (4) from 1-*t*-Boc-glucorapassicin A (10) represents the first biomimetic synthesis of 4, which points to a Lossen type rearrangement catalyzed by TFA.

The HRMS spectral data of product X (C₁₆H₁₈N₂O₆S, calc. 366.0886, obtained 366.0877) indicated the loss of both



Scheme 6 Chemical transformations of 1-EWG-glucorapassicins A 9 and 10 in acidic and basic media (EWG = electron withdrawing group).




Fig. 1 Possible chemical structures of compound X (**14**) ($C_{16}H_{18}N_2O_6S$) and selected HMBC correlations.

methanesulfonyl and sulfate groups ($CH_3SO_2 + SO_4K$) from 1-MeSO₂-glucorapassicin A (**9**) ($C_{17}H_{21}N_2O_{12}S_3$), and *t*-Boc and sulfate groups ($Me_3CCO_2 + SO_4K$) from 1-*t*-Boc-glucorapassicin A (**10**) ($C_{21}H_{27}N_2O_{12}S_2$). The ¹H and ¹³C NMR spectroscopic data of compound X (**14**) indicated that the spin systems of the β-D-glucopyranosyl and the indolyl moieties were intact (¹H NMR obtained in CD₃OD). Methylation of product X (MeI/NaH) was carried out to establish the number of free hydroxyl substituents present in X (**14**).

MS and NMR spectroscopic data of the methylated derivative **15** were consistent with the presence of three methoxy and one *N*-methyl groups, in addition to the expected methoxy group at C-4 of indole. These results indicated that one of the hydroxyl groups of glucose was not methylated and thus it was likely attached to another atom. Based on the molecular formula of X ($C_{16}H_{18}N_2O_6S$, nine degrees of unsaturation) and comparison of its NMR, HMBC and HMQC spectroscopic data with those of 1-MeSO₂-glucorapassicin A (**9**), either chemical structure A or B appeared likely (Fig. 1). The final proof was obtained by X-ray crystallographic analysis of a single crystal of tetramethyl-X (**15**), establishing the chemical structure of X as A (Fig. 2).

Further examination of the biomimetic synthesis of rapalexin A (Scheme 6) suggested that an efficient route might be achieved if thioglucopyranose tetraacetate were to be substituted for a more economical sulfur donor containing a leaving group. Although sulfonylation of hydroximoyl chlorides has been reported using diverse sulfides, these sulfides do not possess a reasonable leaving




Fig. 2 Single crystal X-ray structure of compound tetramethyl-X (**15**) with thermal ellipsoids at 30% of the probability level and the corresponding chemical drawing.


group, except for thioglucopyranose.¹⁶ For this reason, HS-Si(*i*-Pr)₃ was considered, though it did not appear to have been applied to the sulfonylation of hydroximoyl chlorides. In a first attempt, addition of HS-Si(*i*-Pr)₃ to a solution of hydroximoyl chloride **17** in DCM/Et₃N and reaction monitoring by TLC indicated complete consumption of the starting material in 30 min. HRMS and ¹H NMR data of the reaction mixture indicated a product containing two 1-*t*-Boc-4-methoxyindolyl moieties and one Si(*i*-Pr)₃ group. Further modifications of the reaction conditions and isolation of the intermediate product suggested that it contained bis-indolyl moieties connected by an *O*-silylated thiohydroximoyl anhydride ($-(HON=)C-S-C(=NO-Si(i-Pr)_3)-$). Much to our delight, treatment of this product with a solution of TFA (20–30% in DCM) yielded a mixture that, upon standing in DCM/Et₃N for 60 min, yielded rapalexin A (**4**) and 4-methoxyindole-3-carboxylic acid (**21**) (*ca.* 1 : 1). Varying the reaction temperature or the concentration of HS-Si(*i*-Pr)₃ (1–5 eq.) did not affect product yields. Eventually, a one-pot synthesis of rapalexin A from oxime **16** was carried out in *ca.* 30% yield (Scheme 7).

The formation of product **19** is likely due to an intramolecular [1,4]-*S*- to *O*-silyl migration in the first formed reaction intermediate **17a**, followed by nucleophilic attack of the resulting sulfide **18** on the hydroximoyl carbon of **17**. This silyl migration activates thiohydroximate, a prerequisite for the Lossen type rearrangement to occur, which is further encouraged by the *N*-deprotection of the indolyl moiety (Scheme 7). Previously, [1,4]-*S*- to *O*-silyl migrations were reported to proceed intramolecularly and transformed esters into ketones using organolithium reagents.¹⁷


As summarized in Scheme 8, hydrolysis of 1-*t*-Boc-glucorapassicin A (**10**) under acidic conditions is likely to yield the unstable intermediate thiohydroxamic acid **22**, which undergoes a spontaneous Lossen type rearrangement to yield rapalexin A (**4**). These chemical transformations, similar to the formation of isothiocyanates in plants, lend further support to the proposed rapalexin A biosynthetic pathway.⁸ Likewise, transformation of 1-MeSO₂-glucorapassicin A (**9**) under acidic conditions yields 1-MeSO₂-rapalexin A (**11**). By contrast, in basic media (K₂CO₃/MeOH), a skeletal rearrangement of 1-*t*-Boc-glucorapassicin A (**10**) and 1-MeSO₂-glucorapassicin A (**9**) yields the unique product X (**14**), likely *via* the azirine intermediate **23** that undergoes a Neber type rearrangement upon nucleophilic attack by the HO-(C-2) of glucose. This transformation appears to generate the first preparation of a 1-deoxy-1-thioimidocarbonyl-β-D-glucopyranose heterocyclic ring system.¹⁸ Recently, reactions of silyl-protected enol diazoacetates with nitrile oxides were reported to yield rearrangement products *via* dipolar cycloadditions followed by either Neber or Lossen rearrangements.¹⁹

In summary, the first biomimetic synthesis of rapalexin A (**4**) instigated a novel one-pot preparation that revealed a novel application of the Lossen rearrangement. Furthermore, the first bicyclic glucose-fused product (**14**) formed *via* Neber rearrangement was discovered. The scope of these transformations and other approaches to synthesize glucorapassicin A (**2**) are currently under investigation.

We thank the Natural Sciences and Engineering Research Council of Canada (Discovery Research Grant to MSCP),



Scheme 7 One-pot synthesis of rapalexin A (**4**) (structures in brackets are proposed intermediates).



Scheme 8 Proposed intermediates involved in the formation of rapalexin A (**4**) and *N*-(4-methoxy-3-indolyl)-1-thioimidocarbonyl- β -D-glucopyranose (**14**) through Lossen and Neber type rearrangements, respectively.

the Canada Research Chairs Program, the Canada Foundation for Innovation, and the University of Saskatchewan (graduate scholarship to HT) for financial support; the technical assistance of K. Thoms and K. Brown (HREI-MS and NMR data, respectively), Department of Chemistry and SSSC, and P. Groschulski (synchrotron data collection for the crystal structure of **15**), CLS, Saskatoon, is gratefully acknowledged.

Notes and references

- 1 N. Agerbirk and C. E. Olsen, *Phytochemistry*, 2012, **77**, 16.
- 2 M. J. Garson and J. S. Simpson, *Nat. Prod. Rep.*, 2004, **21**, 164.
- 3 P. Gupta, B. Kim, S.-H. Kim and S. K. Srivastava, *Mol. Nutr. Food Res.*, 2014, **58**, 1685.
- 4 F. S. Hanschen, E. Lamy, M. Schreiner and S. Rohn, *Angew. Chem., Int. Ed.*, 2014, **53**, 11430.
- 5 M. S. C. Pedras, Q.-A. Zheng and R. S. Gadagi, *Chem. Commun.*, 2007, 368.

- 6 M. S. C. Pedras, E. E. Yaya and E. Glawischnig, *Nat. Prod. Rep.*, 2011, **28**, 1381.
- 7 For recent reviews: (a) E. A. Schmelz, A. Huffaker, J. W. Sims, S. A. Christensen, X. Lu, K. Okada and R. J. Peters, *Plant J.*, 2014, **79**, 659; (b) P. Bednarek, *ChemBioChem*, 2012, **13**, 1846.
- 8 M. S. C. Pedras and E. E. Yaya, *Org. Biomol. Chem.*, 2013, **11**, 1149.
- 9 H. L. Yale, *Chem. Rev.*, 1943, **33**, 209.
- 10 C. O'Brien, *Chem. Rev.*, 1964, **64**, 81.
- 11 T. Ooi, M. Takahashi, K. Doda and K. Maruoka, *J. Am. Chem. Soc.*, 2002, **124**, 7640.
- 12 P. Rollin and A. Tatibouët, *C. R. Chim.*, 2011, **14**, 194.
- 13 K.-C. Liu, B. R. Shelton and R. K. Howe, *J. Org. Chem.*, 1980, **45**, 3916.
- 14 M. H. Benn, *Can. J. Chem.*, 1964, **42**, 2393.
- 15 M. G. Ettlinger and A. J. Lundeen, *J. Am. Chem. Soc.*, 1957, **79**, 1764.
- 16 B. C. Lemerrier and J. G. Pierce, *Synlett*, 2015, DOI: 10.1055/s-0035-1560700.
- 17 X. Sun, Z. Song, H. Li and C. Sun, *Chem. – Eur. J.*, 2013, **19**, 17589.
- 18 S. Ishiguro and S. Tejima, *Chem. Pharm. Bull.*, 1968, **16**, 2040.
- 19 X. Xu, D. Shabashov, P. Y. Zavalij and M. P. Doyle, *J. Org. Chem.*, 2012, **77**, 5313.